Genep Raises $1.45 Million Seed Financing

GenEp, Inc., a biotechnology company developing therapies that address unmet needs in patients with epilepsy, announced today the closing of a $1.45 million seed financing. The financing was co-led by the UVA Licensing & Ventures Group Seed Fund, Angelini Lumira Biosciences Fund and 3B Future Health Fund, with additional participation by the Virginia Innovation Partnership Corporation, Kids Connect Charitable Fund, PDI Ventures and the company's management team. GenEp is developing first-in-class, highly selective compounds that modulate sodium channels. Nav1.6 & Nav1.2 gain of function mutations drive uncontrolled seizures and result in treatment resistance in certain rare genetic epilepsies and other treatment resistant epilepsies.